Combination of Two Immunotherapies Brings Advanced Melanoma Survival Rate to 50% for First Time

By combining two existing therapies, researchers at the Royal Marsden NHS Foundation Trust in London have found that they have been able to stop or even reverse the progression of advanced melanoma in half of patients. The two therapies, ipilmumab and nivolumab, were tested on patients over the course of five years. The findings were published online ahead of print in the New England Journal of Medicine (Sept. 28, 2019).

Melanoma survival rate in US higher in states with more diagnosed cases

Patients in the United States who live in a state with a higher incidence of melanoma are more likely to survive the disease. Conversely, Americans who live in a state with a lower incidence of melanoma are less likely to survive the disease. Researchers believe that this seeming contradiction might be a result of better detection in more well-funded regions leading to better outcomes.